Novel prognostic scoring system after surgery for klatskin tumor

American Surgeon

Volumn 79, Issue 1, 2013, Pages 90-95

  Kaiser, Gernot M ^a   Paul, Andreas ^a   Sgourakis, George ^a   Molmenti, Ernesto P ^b   Dechene, Alexander ^a   Trarbach, Tanja ^a   Stuschke, Martin ^a   Baba, Hideo A ^a   Gerken, Guido ^a   Sotiropoulos, Georgios C ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; KLATSKIN TUMOR; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PREDICTION; PROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMORADIOTHERAPY; BILE DUCT TUMOR; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; HEPATIC DUCT; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HEPATIC DUCT, COMMON; HUMANS; KLATSKIN'S TUMOR; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84875063593     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Altemeier WA, Gall EA, Zinninger MM, Hoxworth PL. Sclerosing carcinoma of the major intrahepatic bile ducts. Arch Surg 1957;75:459-61.
2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. Am J Med 1965;38:241-56.
3. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg 2009;250:210-8.
4. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366:1303-14.
5. Lang H, Kaiser GM, Zǒpf T, et al. Surgical treatment of hilar cholangiocarcinoma. Chirurg 2006;77:325-34.
6. Li J, Kuehl H, Grabellus F, et al. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 2008;98:438-43.
7. Daniel D, Nicolas D, Pierre-Alain C. Classification of surgical complications. Ann Surg 2004;240:205-13.
8. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg 2009;250:210-8.
9. Gerhards MF, van Gulik TM, de Wit LT, et al. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma -a single center experience. Surgery 2000;127:395-404.
10. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507-17; discussion 517-9.
11. Kondo S, Hirano S, Ambo Y, et al. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins. Results of a prospective study. Ann Surg 2004;240:95-101.
12. Nagino M, Kamiya J, Kanai M, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery 2000;127:155-60.
13. Kelley ST, Bloomston M, Serafini F, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004;70:743-8; discussion 748-9.
14. Minsky BD, Kemeny N, Armstrong JG, et al. Extrahepatic biliary system cancer: an update of a combined modality approach. Am J Clin Oncol 1991;14:433-7.
15. McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997;174:605-8.